Cell 2026
12 November 2026 – 13 November 2026
Novotel London West, London, United Kingdom
Cell is Oxford Global's event for bioprocessing and advanced therapy professionals, bringing together leaders from pharma, biotech, academia and regulatory institutions across the cell culture and cell & gene therapy value chain. The 2026 edition runs over two days in London with three programmes (Cell Culture & Bioprocessing, Advanced Therapy Development, and Cell & Gene Therapy Manufacturing), alongside an Investment Forum and a pre-event workshop by Sony Biotechnology on 11 November.
173 sessions · 138 speakers
Organiser (1)
Sponsors (38)
Green Elephant Biotech · GemPharmatech · Thermo Fisher · Aspetic Technologies · Sapio Sciences · Cell Signaling Technology · Lonza AG · BPES · Alphalyse · Getinge · Beckman Coulter · Infors-HT · IotaSciences · RoslinCT · Roche Diagnostics Deutschland · Eppendorf · Succession bio · Invert Bio · Sartorius Stedim Biotech GmbH · Abselion · ACROBiosystems · PROGEN · Biomerieux · LUMICKS · BioDock · Bramble Bio · Haier Biomedical · Celltrio · Biothrust · Biocair · Repligen · Novo Nordisk Pharmatech · SGS · Biolife Solutions · Ingenza · Air Products · Miltenyi Biotec, Ltd. · EUROFINS DSC PRODUCT TESTING
Startups (7)
Verixus Labs · Data Curators B.V. · Bright Biotech · PartitionBio Ltd · baSeq · HOYA Consulting · ZOMP
Speakers (138)
- Lindsay Davies CSO, NextCell Pharma and CEO, QVance, NextCell Pharma
- Ahmed Abdulgawad Haematology Consultant, Cellular Therapy and Early Phase Trials, NHS
- Gabriel Wong Senior Medical Director, Early Respiratory and Immunology, AstraZeneca
- Seema Bansal Scientific Director, Cell Therapy Analytical Development, CTD, Bristol Myers Squibb
- Stephan Krause Executive Director, BMS
- Ajan Reginald Managing Director, Roquefort Therapeutics
- Josh Bagley Chief Scientific Officer, a:head bio
- Ruth Faram Chief Scientific Officer And Co-Founder, symphoRNA
- Takis Athanasopoulos Head of Gene Therapy, MHRA
- Raphael Ognar President & CEO, Co-founder, NKILT Therapeutics Inc.
- Victor Hernandez CSO, Axovia Therapeutics
- Killian Hanlon CEO, Lir Therapeutics
- Ben Weil Chief Operating Officer & Chief Manufacturing Officer, InmuneBio
- Jacqueline Barry Chief Clinical Officer, Cell and Gene Therapy Catapult
- Peter Andersen Chief Research & Development Officer, TREEFROG THERAPEUTICS
- Owen Bain Director/Qualified Person, Cell & Vector Innovation Centre, Royal Free London NHS Foundation Trust
- Amelia Lane Director Preclinical Development, MeiraGTx
- Mark Eccleston CEO, ValiRx
- Natalie Francis Head of Process Development, King's College London
- John Bridgeman CSO, ImmunoKey
- Omid Mashinchian Global Clinical Strategy Manager, Nestlé
- Anne-Sophie Thorup Cell Culture Scientist, Servier Symphogen
- Bo Wiinberg Chief Business Development Officer, Novo Nordisk Foundation Cellerator
- Busola Ade-Ojo Chief RadioPharmacist and Head of Radiopharmacy Department, NHS
- Claudio Mussolino Group Leader, Medical Center - University of Freiburg
- Edoardo Prediletto Analytical Development Senior Scientist, Autolus
- François Gianelli Chief Regulatory and Quality Officer, TreeFrog Therapeutics
- Helene Boland Senior Associate Global Regulatory, Hogan Lovells
- Marcelo Rivolta Chief Scientific Officer, Rinri Therapeutics
- Roelof Rongen Co-Founder & Board Director, AeirBio, Inc.
- David Brühlmann Global Head of Biologics Technology, Roche
- Frederik De Vos Senior Director, CAR-T Quality, Janssen Pharmaceutical Companies of Johnson & Johnson
- Agnieszka Jozwik Senior Research Scientist, Functional Genomics, AstraZeneca
- Anna Hoy Associate Director, Pre-clinical Development, Resolution Therapeutics
- Bernd Schmidt Chief Technical Officer, Sensorion
- Emma Chan Director, Technical Development, Orchard Therapeutics
- Giandomenico Turchiano Team Leader, University College London
- James Fleming Scientist, AstraZeneca
- Jiawei Gu Senior Director, Cell Therapy Product Leader, Bristol Myers Squibb
- Kirsty Sharplin Transplant Physician & Medical Director, John Radcliffe Hospital
- Laura Marie Deedigan Head of Analytical Sciences, Cell Therapy, Fast-Track Ventures & LIfT BioSciences
- Manohar Bance Professor of Otology, University of Cambridge
- Marc Davies Vice President, R&D, Leucid Bio
- Maryam Shariatzadeh Senior Scientist, Rinri Therapeutics
- Michaela Semeraro Professor & Hospital Practitioner, Paediatrics, Greater Paris University Hospitals
- Oliver Hemmings Investment Analyst, Delin Ventures
- Reinhold Medina Professor, University of Liverpool
- Simon Brunner Senior Principal, Flagship Pioneering
- Diana Hernandez Director of Immune and Advanced Therapies, Anthony Nolan
- Sven Kili Partner, Saisei Ventures
- Leila Abbas Pre Clinical Lead, Rinri Therapeutics
- Alison Caldwell Manager, CMC Regulatory Affairs, Resolution Therapeutics
- Ilya Yasny Partner, LanceBio Ventures
- Davide Danovi Independent Partner, Hoya Consulting
- Marina Tarunina Research Director, Plasticell
- Padraig Donlon Analytical Development Research Scientist, Autolus
- Mohammad El Hajj CEO and Director, Bright Biotech Limited
- Ali Saleemi Lead PAT Expert (Associate Director), Bayer
- Andreas Reimann Principal Scientist, Cell Sciences, Ichnos Glenmark Innovation
- Paolo De Coppi NIHR Professor of Paediatric Surgery, UCL Great Ormond Street Institute of Child Health
- Stephen Ward Chief Technology Officer, Cell and Gene Therapy Catapult, United Kingdom
- Xiaohua Wang Senior Director, Bristol Myers Squibb
- Aleks Guvenel Director - Process Development, Quell Therapeutics
- Carolyn Porter Chief Business Officer, Cell & Gene Therapy Catapult
- Romina Vuono Principal Investigator & Lecturer, Neuroscience, University of Kent, London and South East University Group
- Sharon Barkatullah Head of Analytical Development, Cell and Gene Therapy Catapult
- Alex Boscolo Application Scientist, Repligen Europe B.V.
- Amy Sanders Research Scientist, AstraZeneca
- Antonio Salgado Vice-Dean of Research, University of Minho
- Ashley Shih Cell and Gene Therapy Business Manager, PHC Europe
- Asia Majidi Postdoctoral Scientist, Leibniz Institute for Immunotherapy Regensburg, Germany
- Aya Tarabeine Business Development Manager, Beckman Coulter
- Balazs Sarkadi Professor Emeritus, Hungarian Academy of Science
- Bjorn Onfelt Professor of Applied Physics, KTH Royal Institute of Technology
- Bozena Kaminska Professor, Head of Laboratory, Nencki Institute of Experimental Biology, Polish Academy of Sciences
- Camilla Henriksen Field Application Specialist, Sales & Marketing Europe, Novo Nordisk Pharmatech
- Caraugh Albany Senior Scientist, Autolus Ltd
- Chloe Hurling Associate Senior Bioprocessing Scientist, Cell & Gene Therapy Catapult
- Christopher Knowles Principal Market Development Specialist, Waters
- Clair Gallagher Infrastructure Manager, National Institute for Bioprocessing Research and Training
- David Kentner Senior Principal Scientist, Novartis
- Didier Vilret Application & Technology Director, Aseptic Technologies
- Duncan Borthwick Sales Director, Green Elephant
- Ejvind Mørtz Chief Scientific Officer and Co-Founder, Alphalyse
- Elizabeth Bowler Field Application Specialist (Genomics) UK South, Bio-Rad
- Elodie Bôle-Richard Research Engineer, FC Innov, Bionoveo, France
- Emmanuella Ekadi Senior Bioprocess Scientist, Cell and Gene Catapult
- George Hutchinson International Key Account Manager, Cell Line Development, Nova Biomedical
- Giovanni Campolongo Senior Market Segment Manager Process Analytics, Hamilton
- Guiqin Wu MSAT Indsutrialization Leader, Sanofi
- Hajer Taleb Senior Scientist, Process Development, Resolution Therapeutics
- Hany Meås Staff Scientist, R&D Strategic Alliances R&D, Thermo Fisher Scientific
- Hollie Bartley Director Process Development, Resolution Therapeutics
- Hui Yu Field Application Development Director, ACROBiosystems
- Ian Fotheringham Founder and President, Ingenza Ltd.
- Irina Thiry Lab Manager and Vector Production Technologist, Trellis
- Ivo Urh Field Application Scientist, FUJIFILM
- James Tollitt Senior Scientist, Gene Therapy, MHRA
- Janet Messer Director of Health Data & Digital Policy, Association of the British Pharmaceutical Industry
- Jelle ten Hoeve Chief Executive Officer, Tide Genetics
- Jenny Prange Head of Project Management, Wyss Zurich
- Jeremie Barbau Senior Application Scientist, Repligen Europe B.V.
- Joe Yu Chief Executive Officer, Tiva Biosciences
- Jun Li Head of Preclinical Oncology, GemPharmatech Co., Ltd.
- Kelly Maddison Sales Solution Engineer, Sapio Sciences
- Kerry Hallbrook Associate Principal Scientist, AstraZeneca
- Kevin Cyrys Postdoctoral Researcher, Hannover Medical School
- Kevin Serradas O’Holleran Co-Founder & Chief Executive Officer, ZOMP
- Linn Kreins-Irle Scientist Cell Line & Media Development, BLUU
- Marc Meichenin Co-Founder and Chief Scientific Officer, Clean Cells
- Mark Missen Head of Technical Operations, RoslinCT
- Mark Piskadlo Vice President, Cell Therapy Manufacturing, Bristol Myers Squibb
- Martin De Cecco Head of Technical Specialist Team, Europe, Merck BioReliance
- Martin März Senior Product Manager, PROGEN
- Matthijs Niemeijer Head of Products & Applications, Getinge Bioprocessing
- Melissa Barr Head Of Scientific Operations, ValiRx
- Nicolas Szita Professor of Biochemical Engineering, University College London
- Nicole Lund Senior Director, Analytical & Quality Control, BlueRock Therapeutics
- Oluwatimilehin (Timi) Saba Scientist - Cell Therapy, MHRA
- Patrick Bongartz CEO & Co-Founder, BioThrust
- Patrick Ginty Principal Consultant and Managing Director, VectusBio
- Pierre Springuel Cell & Gene Therapy Specialist, Sartorius
- Rafael Dariolli Co-Founder, CEO and Head of Cardiovascular Modeling, Bonds Biosystems
- Rahul Khanolkar Director, Pre-Clinical Development, Accession Therapeutics
- Romain Joubert Senior Director, Discovery R&D, AviadoBio
- Ruizhi Wang Founder & CEO, Abselion
- Stifani Dougall Gene Therapy Senior Scientist, MHRA
- Timo Peters Senior Technical Sales Specialist, LUMICKS
- Ulrich Rümenapp Senior Lead, Bayer AG
- Zehra Nizami Principal Scientist, Head of Business Development, PartitionBio
- Dnyaneshwar Bhand Principal Scientist DS Process Science, UCB Biopharma UK
- Jose Meseguer Director, Digital & Data Science, Resolution Therapeutics
- Konstantinos Gkatzis Principal, Solyco Capital UK & Europe
- Sarah Domoney Analyst, Saisei Ventures
- Stefano Lomartire Investment Manager, Apposite Capital
- Stephanie Mattsson Director Venture Development, CCRM Nordic
- Thorsten Gorba Senior CMC Advisor, Aspen Neuroscience, Inc.
- Torquil Jackson Investment Manager, Ventures, Cancer Research Horizons
Agenda
Showing 80 of 173 sessions.
- Welcome & Opening Remarks | London Cell Therapy Workshop: Translating the Next Generation of Cell Therapies from Bench to Bedside 11 November 2026 · Lalande & Talbot
- Federation As An Opportunity To Lower The Clinical, Manufacturing And Development Hurdles 11 November 2026 · Lalande & Talbot
- Identifying The Best Starting Material For Cell Therapy - Our Experience With Cord Blood Natural Killer Cells 11 November 2026 · Lalande & Talbot
- Optimised Cell Manufacturing Workflow To Generate CAR-T Cells From Whole Blood 11 November 2026 · Lalande & Talbot
- Sponsor 5-minute Flash Talks 11 November 2026 · Lalande & Talbot
- T Stem Cell Memory Manufacturing For Long-Lived, High-Efficacy T-Cell Therapies 11 November 2026 · Lalande & Talbot
- Hindsight Is 20/20: Lessons Learned From Developing A Retinal Cell Therapy 11 November 2026 · Lalande & Talbot
- Recent Developments And Trends In The Regulatory Landscape For Manufacturing Cell Therapies 11 November 2026 · Lalande & Talbot
- What Happens After You Hit Send: A Junior Investor's View of Your Pitch Deck 11 November 2026 · Lalande & Talbot
- Closing Remarks 11 November 2026 · Lalande & Talbot
- From Cells To Patients: Connecting Innovation, Development & NextGen Technologies In Advanced Therapies To Drive Progress In The Field 12 November 2026 · Conference Room 1
- Accelerating Viral Gene Therapy Delivery With AI 12 November 2026 · Conference Room 5
- Designing Large Scale Cell Therapies For Real-World Access 12 November 2026 · Conference Room 6
- Use Of Temporal Profile Predictions In Cell Culture 12 November 2026 · Conference Room 2
- Accelerating Upstream Process Development Through Data-Driven Cell Culture 12 November 2026 · Conference Room 2
- Potency Starts At The Synapse: Seeing Which T Cells Engage, At Flow Scale 12 November 2026 · Conference Room 7
- Vector Design, CMC, & Impurity Dynamics - A Biologist's Consideration 12 November 2026 · Conference Room 3
- Engineered Cell Lines To Enable Multi-Specific Antibody Development 12 November 2026 · Conference Room 1
- Quality By Design: Tailoring QC Strategies For ATMP Development 12 November 2026 · Conference Room 4
- Building Advanced Therapies Beyond The Science Lessons From Translating Innovation Into Clinical And Commercial Success Applicable 12 November 2026 · Conference Room 7
- Beyond Common Serotypes: New Tools For AAV Quantification 12 November 2026 · Conference Room 4
- Precision That Translates: ddPCR From Discovery To Clinic 12 November 2026 · Conference Room 3
- Astraveus Presentation 12 November 2026 · Conference Room 7
- Choosing the Clone That Scales: Process-Controlled, Fed-Batch Screening of 96 Clones in Parallel with the Cydem VT Automated Clone Screening System 12 November 2026 · Conference Room 1
- Where Does Big Pharma Stand In CGTs – And What Comes Next? 12 November 2026 · Conference Room 5
- Protein Impurities In Cell and Gene Therapies - Regulatory Expectations and LC-MS Best Practice 12 November 2026 · Conference Room 2
- Verixus Labs Poster Presentation - Optimisation Of CHO Cell Growth Medium Using The Verixus AI Platform 12 November 2026 · Conference Room 7
- Lost in Translation? Developing In Vitro Models That Better Predict Multi-RNA Therapeutics 12 November 2026 · Conference Room 1
- Great Edit. Now Prove It! — Why Sanger Sequencing And TIDE GxP Have Their Place In Approved Gene And Cell Therapies. 12 November 2026 · Conference Room 7
- Scale-Up: How To Achieve Faster And More Robust Execution? 12 November 2026 · Conference Room 2
- Method Bridging And Comparability In CGT: Building An Analytical Control Strategy That Lasts 12 November 2026 · Conference Room 4
- vMiX: A Modular AAV-Delivered miRNA Platform For Precise, Durable Gene Silencing Across Indications 12 November 2026 · Conference Room 5
- The Development Of The AXIS Trial. Gene Therapy To Halt The Retinal Degeneration In Bardet-Biedl Syndrome 12 November 2026 · Conference Room 3
- From Academia To Clinical Trials: A Collaborative Journey Between CGT Catapult And Rinri Therapeutics For Successful Development And Delivery Of ATMPs 12 November 2026 · Conference Room 6
- Validating Rapid Mycoplasma Methods For Cell & Gene Therapies: A Roadmap To EP 2.6.7 And USP <77> Compliance 12 November 2026 · Conference Room 4
- Where Advanced Therapies Will Be In 2030: Scientific, Clinical, Regulatory & Economic Futures 12 November 2026 · Conference Room 5
- Optimizing Upstream Bioprocess Efficiency With GlucoSense - From Offline Sampling To Real-Time Glucose Optical Control 12 November 2026 · Conference Room 2
- Informed Clone Selection Through Integrated, CQA-Driven Decision-Making In Early Cell Line Development 12 November 2026 · Conference Room 1
- Improving AAV9 Manufacturing Performance With pPLUS® Plasmids And Data-Driven Process Optimisation 12 November 2026 · Conference Room 3
- Cell, Vector And Media Engineering To Facilitate Manufacture Of ‘Difficult-To-Express’ Products 12 November 2026 · Conference Room 2
- Development Of A WHO Approved Phenotypic Flow Standard For Mesenchymal Stromal Cells 12 November 2026 · Conference Room 4
- TROCEPT: A Tumour Targeted Precision Virotherapy Enabling Tumour Localised Expression Of Immunomodulatory Payloads 12 November 2026 · Conference Room 3
- Outsourcing Biologics’ CMC Development And Manufacturing – Considerations For Supplier Selection 12 November 2026 · Conference Room 6
- Vector Design As The Strategic Lever In Biologics Development 12 November 2026 · Conference Room 1
- Manufacture Of AVB-406, A BBB-Crossing AAV Vector For MAPT Knockdown In Alzheimer's Disease 12 November 2026 · Conference Room 5
- Biological Reference Materials For The Advanced Therapy Field 12 November 2026 · Conference Room 4
- Advancing CGT Scale-Up With Animal-Free Reagents: From Dissociation To Expansion 12 November 2026 · Conference Room 1
- One Sensor, Beyond Monitoring: From Live-Cell Metabolic Profiling to Automated Cell Expansion 12 November 2026 · Conference Room 2
- Assuring Quality At Speed: Enabling Timely Release Of Autologous Cell Therapies 12 November 2026 · Conference Room 6
- A Versatile HEK293 Cell Culture Medium Enables Various Intensified AAV Production Processes 12 November 2026 · Conference Room 5
- Closing The Loop On Autologous Monocyte Selection: The CliniMACS Prodigy In The RTX001 Process 12 November 2026 · Conference Room 4
- Large-Scale Production Of Human Pluripotent Stem Cell Derived Cardiomyocytes 12 November 2026 · Conference Room 6
- World Record Cell Densities: Success Stories After 2 Years Of Membrane Stirrer Bioreactors 12 November 2026 · Conference Room 2
- From Organoids to Decisions: Automated Imaging for Predictive 3D In Vitro Models 12 November 2026 · Conference Room 1
- SGS Presentation 12 November 2026 · Conference Room 4
- Quality Control Strategies In Advanced CGTs 12 November 2026 · Conference Room 4
- Featured Session: Gene Therapy For Hearing Loss 12 November 2026 · Conference Room 3
- Developing In Vitro, Ex Vivo And Mouse Models Of Paediatric High Grade Gliomas For Preclinical Testing 12 November 2026 · Conference Room 1
- Building Investor Confidence And Translating Science Into Value 12 November 2026 · Conference Room 7
- Manufacturing Next-Generation Therapeutic Modalities 12 November 2026 · Conference Room 2
- Cracking In Vivo Delivery For Next-Generation Gene Therapies 12 November 2026 · Conference Room 5
- The AI Reality Check: What’s Ready Now, What Isn’t, And How Do We Validate It Safely? 12 November 2026 · Conference Room 6
- Next-Generation CHO Cell Lines: Built for Speed and Complexity 12 November 2026 · Conference Room 1
- Featured Session: Developing A World-First Regenerative Cell Therapy For Hearing Loss 12 November 2026 · Conference Room 3
- Investing In ATMP Platforms And Enabling Technologies 12 November 2026 · Conference Room 7
- Cell Next-Generation CHO Cell Lines: Built For Speed And Complexity 12 November 2026 · Conference Room 1
- Enabling Affordable Gene Therapies Through Continuous Viral Vector Manufacturing 12 November 2026 · Conference Room 2
- Development Of AAV Physical Reference Materials 12 November 2026 · Conference Room 5
- Harnessing Digital PCR For Rapid Sterility Testing 12 November 2026 · Conference Room 6
- Uncovering The Analytical Iceberg: From Early Uncertainty To Commercial Readiness For Cell Therapy 12 November 2026 · Conference Room 4
- The Future Of Engineering Cell Lines 12 November 2026 · Conference Room 1
- Rethinking Fill-Finish For Cell & Gene Therapies: How A Closed Vial Platform Enables Annex 1-Compliant Contamination Control 12 November 2026 · Conference Room 4
- The AI Native Bioprocessing Platform 12 November 2026 · Conference Room 2
- Overcoming Production Barriers for Complex Biologics using Machine Learning and Appropriate Host Selection 12 November 2026 · Conference Room 1
- Founders Ask Investors: Open Q&A 12 November 2026 · Conference Room 7
- Founders Ask Investors Presentation 1 - PartitionBio: An Innovative Liquid Droplet Platform Technology For Cell Delivery 12 November 2026 · Conference Room 7
- Finding Winners Earlier: Leveraging Next-Generation Technologies to Advance Bioprocessing Research 12 November 2026 · Conference Room 2
- Featured Session: From Bench To Bedside: Advancing AAV Gene Therapy For Hearing Loss 12 November 2026 · Conference Room 3
- Installing Durable Exhaustion-Resistant Features In CAR T Cells By Hit-And-Run Epigenetic Editing 12 November 2026 · Conference Room 5
- Developing Cutting-Edge Flow-Based Assays For Critical CMC Applications 12 November 2026 · Conference Room 6